2026年11月4日星期三
M
Panorama Universal
Notícias globais
Mitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaMitsui Chemicals to buy Japan chip material maker JSR for over $8.2bn— 日经 Nikkei AsiaPetrovietnam CEO sees a future of nuclear and wind power— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Fonte 柳叶刀 LancetHá 11 dias
Resumo do conteúdo

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Este site fornece apenas o título e o índice do resumo; o conteúdo completo e os direitos autorais pertencem ao publicador original. Clique no link do texto original para ler.

Ir para o texto original
Canal de origem
Saúde
Região de origem
Reino Unido
Idioma do texto original
English
Número do item
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Panorama Universal